Megan Blewett is the co-founder and President of Iris Medicine, whose mission is to develop genetically targeted treatments for neurodegenerative disorders.
Prior to Iris, Megan co-founded Kelonia Therapeutics, a company advancing tissue-specific gene delivery. Megan was previously a venture capital investor at Venrock with an emphasis on therapeutics and biotech company creation.
Megan earned a PhD in chemistry as a Hertz fellow with Benjamin Cravatt at The Scripps Research Institute. Her PhD work helped form the foundation of Vividion, which was acquired by Bayer in 2021. Megan received her AB/AM from Harvard, where she conducted research in the lab of Novel laureate EJ Corey. She has been named to the Forbes 30 under 30 list for Healthcare and Business Insider’s Under 40 in Biotech.
In addition to her work in biotech, Megan serves on the Board of two non-profits, Convergent Research and Pioneer Labs, that are dedicated to advancing early-stage research in areas of high unmet need.
